Endotoxin shock due to Vibrio vulnificus infection

European Journal of Dermatology

Volumn 16, Issue 4, 2006, Pages 423-427

  Ikeda, Takaharu ^a   Kanehara, Shoko ^b   Ohtani, Toshio ^a   Furukawa, Fukumi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Rinku General Medical Center   (Japan)

Author keywords

Corticosteroid; Hemoperfusion; Interleukin 6; Intravenous immunoglobulin (IVIg); Polymyxin B immobilized fiber (PMX F); Vibrio vulnificus

Indexed keywords

CEFOTIAM; CORTICOSTEROID; HYDROCORTISONE; IMMUNOGLOBULIN; INTERLEUKIN 6; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; DISEASE SEVERITY; ENTEROCOLITIS; ERYTHEMA; GRAM NEGATIVE INFECTION; HEMOPERFUSION; HEPATITIS C; HUMAN; MALE; SEPTIC SHOCK; SKIN BIOPSY; SKIN CULTURE; VIBRIO VULNIFICUS;

HUMANS; MALE; MIDDLE AGED; SHOCK, SEPTIC; VIBRIO INFECTIONS; VIBRIO VULNIFICUS;

EID: 33748305518     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hsueh PR, Lin CY, Tang HJ, et al. Vibrio vulnificus in Taiwan. Em Infect Dis 2004; 10: 1363-8.
2. Kojo Y, Johno M, Nakagawa K, Ono T. Vibrio vulnificus infection: Strategy for diagnosis and treatment. Jpn J Dermatol 1999; 109: 875-84; (in Japanese).
3. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995; 23: 1294-303.
4. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-9.
5. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock: a systemic review and meta-analysis. BMJ 2004; 329: 480.
6. Minneci PC, Katherine JD, Banks SM, et al. Meta-analysis: The effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141: 47-56.
7. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: An evidence-based review. Crit Care Med 2004; 32: S527-S533.
8. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71.
9. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiolosic doses of hydrocortisone. Crit Care Med 1998; 26: 645-50.
10. Kodama M, Tani T, Hasegawa K, et al. Treatment of sepsis by plasma endotoxin removal: hemoperfusion using a polymyxin-B immobilized column. J Endotoxin Res 1997; 4: 293-300.
11. Sato T, Tadakuma N, Ikezaki N, et al. Endotoxin removal column containing polymyxin B immobilized fiber is useful for the treatment of the patient with Vibrio vulnificus septicemia. Artif Organs 1998; 22: 705-7.
12. Sato T, Shoji H, Koga N. Endotoxin absorption by polymyxin B immobilized fiber column in patients with systemic inflammatory response syndrome: The Japanese experience. Ther Apher and Dial 2003; 7: 252-8.
13. Tani T, Hasegawa K, Endo Y, et al. Therapeutic apheresis for septic patients with organ dysfunction: Hemoperfusion using a polymyxin B immobilized column. Arfif Organs 1998; 22: 1038-44.
14. Chiang SR, Chuang YC. Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 2003; 36: 81-8.
15. Chuang YC, Ko WC, Wang ST, et al. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 1998; 42: 1319-22.
16. Oonaka K, Furuhata K, Kikuchi A, et al. A basic study of Vibrio vulnificus infection: Serotyping and drug sensitivity test of environment-derived strains and human clinical isorates. Kansenshogaku Zasshi 2004; 78: 83-9; (in Japanese).
17. Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-62.
18. Shin SH, Shin DH, Ryu PY, et al. Proinflammatory cytokine profile in Vibrio vulnificus septicemic patients' sera. FEMS Immunol Med Microbiol 2002; 33: 133-8.
19. Calandra T, Gerain J, Heumann D, et al. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991; 91: 23-9.
20. Damas P, Canivet JL, Groote DD, et al. Sepsis and serum cytokine concentrations. Crit Care Med 1997; 25: 405-12.
21. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: Hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001; 12: S70-S74.
22. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low dose" hydrocortisone in septic shock. A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167: 512-20.
23. Tani T, Hasegawa K, Kodama M, et al. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 in septic patients. World J Surg 2001; 25: 660-8.
24. Ikeda T, Ikeda K, Nagura M, et al. Clinical evaluation of PMX-DHP for hypercytokinemia caused by septic multiple organ failure. Ther Apher and Dial 2004; 8: 293-8.
25. Suzuki H, Ikeda T, Ikeda K. Changes in various cytokines and mediators by the administration of IVIg in sepsis patients. ICU&CCU 2004; 28: 119-24; (in Japanese).